source clustersSource Clusters is the single source of information on regional development in the life sciences sector worldwide.

With content providing broad overviews as well as in-depth coverage of business development trends, company activities, life science cluster collaborations, multi-partner scientific projects and its extensive news coverage, Source Clusters presents the latest management, research, technology and regional development information serving the needs of executives in the internationally growing life sciences sector.

Source Clusters is the essential resource for companies, incubators, science parks, clusters and regional development agencies looking to find a new location or attract new business and exploit new opportunities across the life sciences sector.

Phico Therapeutics appoints financial director and two non-executive directors

Antibiotics developer Phico Therapeutics Ltd has appointed Andrew Armour as its financial director and Professor Mark Wilcox and David Beadle as non-executive directors. The appointments have been made to support the progression of the company’s lead product, SASPjec PT3.8, through clinical trials and the financing of its planned clinical-grade manufacturing facility. SASPject PT3.8 has been developed for the intravenous treatment of hospital infections due to the bacterium Pseudomonas aeruginosa utilising unique antibacterial small acid-soluble spore proteins to target and deactivate bacterial DNA.

Phico Therapeutics Andrew Armour 19.1.19Andrew Armour is a chartered accountant with experience in the health care industry, particularly in financial restructuring, equity fundraising and corporate acquisitions and disposals. He previously held positions at Grant Thornton and Deloitte, working on restructuring and corporate finance assignments, before becoming the financial director of Colchester Hospital in the UK.

Phico Therapeutics Professor Mark Wilcox 19.1.19Professor Mark Wilcox has held several positions at the Leeds Teaching Hospitals and is currently a consultant microbiologist and head of research and development in microbiology and professor of medical microbiology at the University of Leeds. He has extensive clinical experience in infectious diseases and advises Public Health England and NHS England on diagnosis, prevention and development of infection prevention and control products and new antimicrobial agents to target health care-associated infections. He has been involved with Phico for a number of years from representing the Wellcome Trust (WT) as the company’s expert on Phico’s two WT Awards, and will now further support Phico in progressing SASPject PT3.8 through clinical trials.

Phico Therapeutics David Beadle 19.1.19David Beadle has more than 25 years’ experience within health care and finance, having worked in marketing and strategic development at Schwarz Pharma and Schering AG before moving into investment banking, where he built and led highly ranked health care equity research teams both globally and across Europe for over 10 years. He is specialised in consulting on scientific, corporate finance and business development strategies within the health care and biotechnology field and joins Phico to primarily advise on strategies for business development.

For further information about Phico Therapeutics visit www.phicotx.co.uk

Last modified onMonday, 28 January 2019 14:01

Latest from Tom Mulligan